Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lung Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 63Androgen Antagonists 59Abiraterone Acetate 57apalutamide 55Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 46abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Follow-Up Studies × 1 year × Clear all
NCT07291414 2026-01-21

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

Phase NA Recruiting
80 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡